Alkermes/$ALKS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Ticker
$ALKS
Sector
Primary listing
Employees
1,800
Headquarters
Dublin, Ireland
Website
Alkermes Metrics
BasicAdvanced
$4.8B
13.92
$2.08
0.40
-
Price and volume
Market cap
$4.8B
Beta
0.4
52-week high
$36.45
52-week low
$25.56
Average daily volume
1.8M
Financial strength
Current ratio
3.232
Quick ratio
2.712
Long term debt to equity
4.076
Total debt to equity
4.474
Interest coverage (TTM)
35.14%
Profitability
EBITDA (TTM)
403.272
Gross margin (TTM)
85.13%
Net profit margin (TTM)
23.15%
Operating margin (TTM)
24.86%
Effective tax rate (TTM)
15.19%
Revenue per employee (TTM)
$840,000
Management effectiveness
Return on assets (TTM)
10.49%
Return on equity (TTM)
23.94%
Valuation
Price to earnings (TTM)
13.922
Price to revenue (TTM)
3.141
Price to book
2.94
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
9.852
Free cash flow yield (TTM)
10.15%
Free cash flow per share (TTM)
2.936
Growth
Revenue change (TTM)
-0.17%
Earnings per share change (TTM)
21.99%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.80%
3-year earnings per share growth (CAGR)
53.04%
10-year earnings per share growth (CAGR)
13.40%
What the Analysts think about Alkermes
Analyst ratings (Buy, Hold, Sell) for Alkermes stock.
Alkermes Financial Performance
Revenues and expenses
Alkermes Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alkermes stock?
Alkermes (ALKS) has a market cap of $4.8B as of August 29, 2025.
What is the P/E ratio for Alkermes stock?
The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 13.92 as of August 29, 2025.
Does Alkermes stock pay dividends?
No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Alkermes dividend payment date?
Alkermes (ALKS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alkermes?
Alkermes (ALKS) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.